A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest^®) for luteal phase support during IVF treatment.

ABSTRACT:

Purpose

The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest^®, marketed as Endometrin^® in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment.

Patients and methods

This questionnaire-based audit included responses from 100 patients undergoing IVF treatment at six IVF clinics in the UK from September 2015 to November 2016. Fourteen days after starting progesterone supplementation for LPS during their IVF treatment, patients rated overall experience and perceived convenience of the prescribed progesterone by completing a questionnaire.

Results

Of the 100 patients included, 96 received vaginal progesterone tablets for LPS. Overall, 53.1% (5

SUBMITTER: Heine P 

PROVIDER: S-EPMC5726362 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature